A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications
about
Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemiaIron deficiency anemia in inflammatory bowel diseaseNanopharmaceuticals (part 2): products in the pipelineSafety of intravenous iron formulations: facts and folkloreConsiderations and challenges in defining optimal iron utilization in hemodialysisIntravenous iron therapy: how far have we come?Incorporation of (57)Fe-isotopically enriched in apoferritin: formation and characterization of isotopically enriched Fe nanoparticles for metabolic studies.Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticlesHypersensitivity reactions to intravenous iron: guidance for risk minimization and management.Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy.Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterialsIntravenous ferric carboxymaltose for the treatment of iron deficiency anemia.The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.Safety and technique of ferumoxytol administration for MRI.Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders.Safety of intravenous iron use in chronic kidney disease.A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)Nanotherapeutics in the EU: an overview on current state and future directions.A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemiaFerric carboxymaltose for the treatment of iron-deficiency anemia. [corrected].State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease.Product quality for nanomaterials: current U.S. experience and perspective.The Labile Side of Iron Supplementation in CKDDistinct immunologic effects of different intravenous iron preparations on monocytesHow we diagnose and treat iron deficiency anemia.The development of a nurse-led iron deficiency anaemia service in a district general hospital.Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment.Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.Single-dose intravenous iron for iron deficiency: a new paradigm.Diagnosis and treatment of anemia in patients with inflammatory bowel disease.The available intravenous iron formulations: History, efficacy, and toxicology.
P2860
Q26750413-2F5A1327-2E9C-42DD-95B4-CEE9003C9537Q26795390-35A54A1B-00A6-4AC9-B541-02D41B4AD280Q26824153-63C19BA0-8BB9-4D9B-B0AB-9B0E9B66C3DAQ26853397-131EC7F6-C75B-49CF-B62E-F3EF7A67DADAQ28088564-8F82B53F-2DA1-4633-8AF9-E995D9F5719AQ28276678-5E09C1E6-ECA0-4491-91B7-B81EC5C1AD96Q30366242-7CE61829-0BDE-4E9F-91BD-D73014713D10Q33691661-CC5383EF-6A26-450F-808E-547218FA212EQ34463623-9C676BFB-1F1B-498A-9E9D-4DEE9E0D5DABQ34735875-547AAE60-CE22-4D1C-96E8-362C0903B0F4Q34884492-5BA90DF8-43A6-4CE4-BF1A-733C08FCEB5DQ35078212-88669430-5A02-4C26-9A47-3CD0010FD59AQ35674624-F88146E9-314F-42F7-994D-C7B7EE00F1F2Q35822161-F926446E-37DC-4ADD-9436-BCA633B90892Q35998091-A793EBCE-282C-4DC7-B873-824FD51BB166Q36076079-EEC86A1C-6363-4F9D-9968-61E2C2B027CAQ36194460-DD38F0A3-ABEA-4173-BF47-E615BCB2AC76Q36287535-BB515214-2776-437E-B585-9DF7B2440F33Q36371086-2456BD34-5091-4662-90E7-1854096FFD1EQ36476581-D67119CD-2071-4BE0-ABFF-3F0F3FD9D382Q36862859-E82F2A89-AA72-400F-BE55-32C22090AF42Q37098701-A2361345-55FD-49C7-9CCE-9CC20BE61C3EQ37320585-6FE6E105-E626-40A5-A99C-5851990E8816Q37352255-EFEA1700-498E-4983-9D6E-DB8EC46593FDQ37368915-68C6661E-8D13-40DF-BF84-61C624A51098Q37601242-7CE29C5A-6DE0-4FD1-9CF1-375636202EF9Q37717825-452D2BA8-5482-4316-8967-5399A301013AQ37993131-9A783F68-7600-44C6-A7A1-7D8C7ED53AC5Q38037260-142654B3-B61F-4908-B834-1E206473C538Q38340318-A72121D6-E359-4863-963B-CF769B99A710Q38496987-F46764E9-19E2-4E75-BB13-8D52A5F3189FQ38541320-1E6EB65B-5861-4169-87B0-C267B076454BQ38593099-B780D363-5D20-439B-9553-E2DC2C2EA004Q38609012-530C3C88-5F79-4208-96AE-BEC983A29D5BQ38714322-A02CBE39-F6D8-4E00-A43A-9191C666A230Q38761669-CA59CD37-A762-4866-8B56-ECFB8A6DB68DQ38946879-9625AD7B-7222-418E-8495-C84BAD008637Q39027699-448063AE-1926-46D8-B886-9CF24C7DA02EQ39044814-2B9131FC-96BE-49CC-AEAC-ADDA8793F631Q39216462-95693B09-786D-41AC-8C4E-99F878554647
P2860
A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A comparative study of the phy ...... and its clinical implications
@ast
A comparative study of the phy ...... and its clinical implications
@en
A comparative study of the phy ...... and its clinical implications
@nl
type
label
A comparative study of the phy ...... and its clinical implications
@ast
A comparative study of the phy ...... and its clinical implications
@en
A comparative study of the phy ...... and its clinical implications
@nl
prefLabel
A comparative study of the phy ...... and its clinical implications
@ast
A comparative study of the phy ...... and its clinical implications
@en
A comparative study of the phy ...... and its clinical implications
@nl
P2093
P50
P3181
P1476
A comparative study of the phy ...... and its clinical implications
@en
P2093
Hans B Andreasen
Klaus Bock
Manuel Muñoz
Markus R Jahn
Peter Langguth
Sören Fütterer
Thomas Nawroth
Volker Schünemann
P304
P3181
P356
10.1016/J.EJPB.2011.03.016
P407
P577
2011-08-01T00:00:00Z